1-9 of 9
Darla Miller
Close
Sort by
Journal Articles

Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Naveen Pemmaraju, Kapil N. Bhalla, Naval Daver, Nathaniel R Wilson, Warren C. Fiskus, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Courtney D. DiNardo, Elias J. Jabbour, Jan A. Burger, Nicholas J. Short, Yesid Alvarado, Nitin Jain, Lucia Masarova, Srdan Verstovsek, Ghayas C. Issa, Wei Qiao, Joseph D. Khoury, Sherry A. Pierce, Darla Miller, Marina Konopleva, Hagop Kantarjian, Gautam Borthakur
Journal: Blood
Blood (2021) 138 (Supplement 1): 3421.
https://doi.org/10.1182/blood-2021-154351
Published: 2021
Journal Articles

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia

Nicholas J. Short, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Guillermo Montalban-Bravo, MD, Prithviraj Bose, MD, Jan A. Burger, MD PhD, Darla Miller, Lynette Alexander-Williams, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-140153
Published: 2020
Journal Articles

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Kelly S. Chien, MD, Mahesh Swaminathan, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Nicholas J. Short, MD, Kelly Soltysiak, PhD, Sherry A. Pierce, BSN, BA, Jane Waukau, BSN, RN, Darla Miller, Jorge E. Cortes, MD, Yesid Alvarado, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4252.
https://doi.org/10.1182/blood-2019-129226
Published: 2019
Journal Articles

Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Joseph D Khoury, MD, Keyur P. Patel, MDPhD, Carlos E. Bueso-Ramos, MD PhD, Naval G. Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Srdan Verstovsek, MD PhD, Naveen Pemmaraju, MD, Zeev Estrov, MD, Darla Miller, Rita Maduike, RN, Stefan Faderl, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2016) 128 (22): 3166.
https://doi.org/10.1182/blood.V128.22.3166.3166
Published: 2016
Journal Articles

A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Elias J. Jabbour, MD, Nicholas J. Short, MD, Xuelin Huang, PhD, Abhishek Maiti, MBBS, Tapan M. Kadia, MD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D DiNardo, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Zeev Estrov, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Yesid Alvarado, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, Darla Miller, Xiao Dong, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2016) 128 (22): 226.
https://doi.org/10.1182/blood.V128.22.226.226
Published: 2016
Journal Articles

Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)

Guillermo Montalban-Bravo, MD, Guillermo Garcia-Manero, MD, Nicholas J. Short, MD, Koji Sasaki, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Courtney DiNardo, MD, Darla Miller, Zeev Estrov, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Elias Jabbour
Journal: Blood
Blood (2015) 126 (23): 2877.
https://doi.org/10.1182/blood.V126.23.2877.2877
Published: 2015
Journal Articles

Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium

Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Mikkael A. Sekeres, MD MS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Gail J Roboz, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Courtney DiNardo, MD, Darla Miller, Zeev Estrov, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Srdan Verstovsek, MD PhD, Hagop M. Kantarjian, MD, Elias Jabbour
Journal: Blood
Blood (2015) 126 (23): 94.
https://doi.org/10.1182/blood.V126.23.94.94
Published: 2015
Journal Articles

Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)

Elias Jabbour, MD, Koji Sasaki, Naval Daver, MD, Naveen Pemmaraju, MD, Courtney D. DiNardo, MD, Tapan Kadia, MD, Darla Miller, Victoria Sukholutsky, Xuelin Huang, PhD, Gautam Borthakur, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2014) 124 (21): 4640.
https://doi.org/10.1182/blood.V124.21.4640.4640
Published: 2014
Journal Articles

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

Aziz Nazha, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Courtney D. DiNardo, MD, Darla Miller, Stefan H. Faderl, MD
Journal: Blood
Blood (2013) 122 (21): 1525.
https://doi.org/10.1182/blood.V122.21.1525.1525
Published: 2013